Synthetic Melatonin Metabolites Appear to Prevent Brain Cell Death
Dec 22, 2005 - 4:32:00 PM
, Reviewed by: Himanshu Tyagi
|
|
|
Like melatonin, the new synthetic compounds apparently can cross biological barriers, suppress iNOS production, and, in turn, prevent NO-induced brain damage, the researchers say.
|
By American Chemical Society,
[RxPG] Spanish chemists have developed a promising set of synthetic compounds that one day could help slow or perhaps halt the progression of Alzheimer's disease and other neurological disorders. The preliminary finding, based on test tube studies by researchers at the Universidad de Granada and others, appears in the Dec. 29 issue of the American Chemical Society's Journal of Medicinal Chemistry.
The compounds, particularly a synthesized metabolite of the hormone melatonin, all inhibit an enzyme called inducible nitric oxide synthase (iNOS), which is needed to produce nitric oxide (NO). NO, a signaling molecule that can activate the immune system, plays an important role in the brain, according to the researchers. But too much NO can trigger the death of brain cells and some scientists theorize the compound is involved in the development of Alzheimer's and Parkinson's diseases.
Like melatonin, the new synthetic compounds apparently can cross biological barriers, suppress iNOS production, and, in turn, prevent NO-induced brain damage, the researchers say. However, they caution that additional research will be needed to verify these results.
Publication:
Dec. 29 issue of the American Chemical Society's Journal of Medicinal Chemistry
On the web:
www.acs.org 
|
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Alzheimer's Newsletter
|
|
|
|
Additional information about the news article
|
The American Chemical Society the world's largest scientific society is a nonprofit organization chartered by the U.S. Congress and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
